TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06107413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: IV Infusion
Study: NCT05355610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Intratympanic gentamicin and dexamethasone administered in two doses one week apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Study: NCT05177133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: IV retifanlimab
Study: NCT04722549

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate
Description: Sodium butyrate
Study: NCT05554965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
Study: NCT05863845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Carmustine
Description: 300mg/m2 day -7, Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300mg/m2 day -7, Given IV

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cytarabine
Description: 100mg/m2/d, day -6 to day -3, Given IV
Study: NCT05516173

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Pressure Monitoring, Ambulatory
Description: To monitor the blood pressure during 24 hours.
Study: NCT05315778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-BCMA chimeric antigen receptor T cells
Description: Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
Study: NCT04545554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Participants will receive multiple doses of romosozumab via a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Participants will receive multiple doses of romosozumab via a SC injection.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: All participants will receive daily supplements of elemental calcium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: All participants will receive daily supplements of elemental calcium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: All participants will receive daily supplementation with vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: All participants will receive daily supplementation with vitamin D.
Study: NCT05665179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Removing Barriers to Recovery
Description: Experimental patients are provided no-cost legal services in-person at addiction treatment centers using an online platform
Study: NCT04781842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing exercise program
Description: Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
Study: NCT06440577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual stimuli (Neutral-Relaxing)
Description: Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of neutral everyday objects (e.g., tools, dirt) and their use (construction, gardening).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual stimuli (Drug)
Description: Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of drug paraphernalia (e.g., syringe, tourniquet, heroin) and preparation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual stimuli (Non-Food)
Description: Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping an everyday object (e.g., box of crayons) and taking out its contents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual stimuli (Food)
Description: Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping a snack (e.g., chocolate bar, bag of chips) and taking out its contents.
Study: NCT06045650

Intervention type: OTHER
Intervention: baseline serum oxytocin levels
Description: Both cases and controls will be assessed for their baseline serum oxytocin levels

Intervention type: OTHER
Intervention: baseline serum oxytocin levels
Description: Both cases and controls will be assessed for their baseline serum oxytocin levels

Intervention type: OTHER
Intervention: Emotional Sensitivity test
Description: To assess the level of emotional sensitivity in the participant

Intervention type: OTHER
Intervention: Emotional Sensitivity test
Description: To assess the level of emotional sensitivity in the participant

Intervention type: OTHER
Intervention: Neuro-economical game
Description: A game played to assess the trust-index of participants

Intervention type: OTHER
Intervention: Neuro-economical game
Description: A game played to assess the trust-index of participants

Intervention type: OTHER
Intervention: Childhood Trauma Questionnaire
Description: to assess childhood trauma score

Intervention type: OTHER
Intervention: Childhood Trauma Questionnaire
Description: to assess childhood trauma score
Study: NCT05412979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-1891
Description: ST-1891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Levothyroxine
Study: NCT05949320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Motivational Interviewing
Description: This study evaluates a 90-day mobile phone-based intervention using the e-Motivational Interviewing app for individuals with chronic conditions like hypertension and diabetes. The app provides short conversations with health messages and reflective questions on lifestyle choices, such as physical activity and diet. The intervention incorporates change talk from Motivational Interviewing and principles from Basic Psychological Needs Theory (BPNT) to encourage positive behavior change. Users interact via multiple-choice questions, promoting self-assessment and reflection. The goal is to facilitate sustained lifestyle changes and improved health outcomes.
Study: NCT04952519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Patients are treated with high doses of amantadine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amantadine
Description: Patients are treated with high doses of amantadine.
Study: NCT04770545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGCETACOPLAN (APL-2)
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGCETACOPLAN (APL-2)
Description: Complement (C3) Inhibitor
Study: NCT06045650

Intervention type: OTHER
Intervention: Relationships Questionnaire
Description: to assess attachment type

Intervention type: OTHER
Intervention: Relationships Questionnaire
Description: to assess attachment type

Intervention type: OTHER
Intervention: demographic questionnaire
Description: To obtain basic data on demographics

Intervention type: OTHER
Intervention: demographic questionnaire
Description: To obtain basic data on demographics
Study: NCT06061484

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ready-to-use therapeutic food (RUTF)
Description: Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use therapeutic food (RUTF)
Description: Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use therapeutic food (RUTF)
Description: Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Standard weight-based dosing per Ehtiopian national guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Standard weight-based dosing per Ehtiopian national guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Standard weight-based dosing per Ehtiopian national guidelines
Study: NCT04887272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training Protocol
Description: EXT: Supervised EXT will include a progressive individualized program that combines aerobic and resistance protocols. Volume progression will begin with 3-days of supervised training sessions/wk and will increase by 1 session/wk to a maximum of 5-days/wk. Each EXT session will include 30 minutes of aerobic training (15 minutes cycling; 15 minutes treadmill walking/running/elliptical) and 30 minutes of resistance training (specifics below). Considering individual fatigue will be a concern, therefore similar to exercise training standards in COPD, the duration of rest periods may be extended (\~1-3 min) as needed, however, all exercise durations will be completed within a 1.5-hour time slot. On days that EXT and IMET interventions overlap, the training and IMET will be spread out over a 2-hour session as opposed to the 1.5-hour time slot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Training Protocol
Description: EXT: Supervised EXT will include a progressive individualized program that combines aerobic and resistance protocols. Volume progression will begin with 3-days of supervised training sessions/wk and will increase by 1 session/wk to a maximum of 5-days/wk. Each EXT session will include 30 minutes of aerobic training (15 minutes cycling; 15 minutes treadmill walking/running/elliptical) and 30 minutes of resistance training (specifics below). Considering individual fatigue will be a concern, therefore similar to exercise training standards in COPD, the duration of rest periods may be extended (\~1-3 min) as needed, however, all exercise durations will be completed within a 1.5-hour time slot. On days that EXT and IMET interventions overlap, the training and IMET will be spread out over a 2-hour session as opposed to the 1.5-hour time slot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle and Exercise Training
Description: Inspiratory Muscle Training (IMT): All IMT sessions will be performed similar to EXT, with the exception of having 2-3-sessions of at-home IMT training depending on where in the exercise progression the individual is (i.e., Week1 vs week 6). On the days that IMT and exercise training overlap, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle and end of the session. Each week will include a measure of Maximal Inspiratory Pressure (MIP) and a Test of Inspiratory Respiratory Endurance (TIRE). The intensity of the IMT will be 50% of the weekly MIP, thus progressive increases in IMT threshold intensity will remain at 50% of the weekly MIP. In contrast, the TIRE protocol will assess respiratory endurance based on the relative baseline intensity. Thus TIRE testing will begin at a MIP intensity of 50% (weeks 1-2), and then progressing to 65% (weeks 3-4), and 80% (weeks 5-6).
Study: NCT06071104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior segment ophthalmic surgery
Description: Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNITY VCS
Description: UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY Cataract FMS Pack, and UNITY Anterior Vitrectomy Kit
Study: NCT06187974

Intervention type: OTHER
Intervention: observation
Description: observation

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT05276154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thermoviscous bulkfill composite (Viscalor)
Description: a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
Study: NCT06107413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion
Study: NCT04670055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA Targeted CAR T-cells
Description: Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
Study: NCT06339632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical phrenic nerve stimulation (TEPNS)
Description: The characteristics of the electrical current: biphasic waves, set at a stimulation frequency of 10 Hz, pulse width of 200 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. The application of TEPNS will initially be performed by defining the trajectory of the phrenic nerve in the cervical region. The negative pole (active point), a stick with a spherical tip for micro-current of 2 mm will be positioned with slight pressure in the region of the phrenic nerve pathway between the two heads of the sternocleidomastoid muscle. Additionally, at the positive pole (passive point), a self-adhesive electrode sized (2.0 x 2.0 cm) will be positioned on the skin in the shoulder region. The intensity, measured in milliamperes (mA), will be adjusted to the maximum tolerated by the patient. The total stimulation time will be 10 minutes, applied continuously in a single session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical diaphragm stimulation (TEDS)
Description: The characteristics of the electrical current are: biphasic waves, set at a stimulation frequency of 30 Hz, pulse width of 400 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. Two self-adhesive electrodes sized (5.0 x 5.0 cm) will be used, positioned in the bilateral parasternal region next to the xiphoid process and the other electrode in the intercostal space between the 6th and 7th ribs bilaterally, at the mid-axillary line. The intensity, measured in milliamperes (mA), will be adjusted to the maximum intensity tolerated by the patient until diaphragmatic contraction is observed with the naked eye, without contraction of other muscles in the abdominal region. The total stimulation time will be 10 minutes, applied continuously in a single session.
Study: NCT05389046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram+Aripiprazole
Description: Escitalopram+Aripiprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram+omega-3 PUFAs
Description: Escitalopram+omega-3 PUFAs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram+Aripiprazole+omega-3 PUFAs
Description: Escitalopram+Aripiprazole+omega-3 PUFAs
Study: NCT06076707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacain-tramadol
Description: Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacain-tramadol
Description: Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacain-tramadol
Description: Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section
Study: NCT05863845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100mg/m2/d, day -6 to day -3, Given IV

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Etoposide
Description: 200mg/m2/d, day -6 to day -3, Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200mg/m2/d, day -6 to day -3, Given IV

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Melphalan
Description: 140mg/m2, day -2, Given IV
Study: NCT05726916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris®
Description: Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
Study: NCT06525727

Intervention type: OTHER
Intervention: Falls Decision Rule
Description: The Falls Decision Rule is a rule used to assess the risk of intracranial haemorrhage in geriatric patients and to prevent brain tomography (CT) in low-risk patients. This rule recommends that brain CT is not necessary in patients who do not have significant head trauma, memory loss or newly developing neurological examination disorder after a fall.
Study: NCT05726916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin angiotensin system blockers
Description: Blood pressure control with renin angiotensin system blockers
Study: NCT06107413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion
Study: NCT04701788

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
Study: NCT06107413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV Infusion
Study: NCT05570916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zip-stitch(R)
Description: Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference suture
Description: Standard suture for vaginal cuff closure during laparoscopic hysterectomy
Study: NCT05863845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140mg/m2, day -2, Given IV

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hematopoietic Cell Transplantation
Description: Undergo hematopoietic cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo hematopoietic cell transplantation
Study: NCT05647291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal Shock wave therapy
Description: Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: 40mg/1ml methylprednisolone, two sessions once a week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
Study: NCT05594641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Description: A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The tourniquet will be applied to the right arm but the cuff will be not inflated
Study: NCT05700617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1:1 Randomization to receive milrinone or dobutamine
Description: Randomized to receive either inotropic agent: milrinone or dobutamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1:1 Randomization to receive dobutamine or milrinone
Description: Randomized to receive either inotropic agent: milrinone or dobutamine